These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21078010)

  • 41. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat.
    Cookson J; Gilaberte I; Desaiah D; Kajdasz DK
    Int Clin Psychopharmacol; 2006 Sep; 21(5):267-73. PubMed ID: 16877897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Duloxetine for the treatment of major depressive disorder in older patients.
    Nelson JC; Wohlreich MM; Mallinckrodt CH; Detke MJ; Watkin JG; Kennedy JS
    Am J Geriatr Psychiatry; 2005 Mar; 13(3):227-35. PubMed ID: 15728754
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressants.
    Nelson JC; Zhang Q; Kelin K; Eriksson E; Deberdt W; Berk M
    Curr Med Res Opin; 2013 Jul; 29(7):827-33. PubMed ID: 23581532
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship between TSH levels in the normal range and short-term duloxetine efficacy.
    Corruble E; Goldberger C; Spann M
    J Affect Disord; 2010 Jun; 123(1-3):312-6. PubMed ID: 19825504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder.
    Arnold LM; Meyers AL; Sunderajan P; Montano CB; Kass E; Trivedi M; Wohlreich MM
    Ann Clin Psychiatry; 2008; 20(4):187-93. PubMed ID: 19034749
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.
    Shelton RC; Andorn AC; Mallinckrodt CH; Wohlreich MM; Raskin J; Watkin JG; Detke MJ
    Int Clin Psychopharmacol; 2007 Nov; 22(6):348-55. PubMed ID: 17917553
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
    Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA
    J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial.
    Arnold LM; Clauw D; Wang F; Ahl J; Gaynor PJ; Wohlreich MM
    J Rheumatol; 2010 Dec; 37(12):2578-86. PubMed ID: 20843911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.
    Detke MJ; Lu Y; Goldstein DJ; McNamara RK; Demitrack MA
    J Psychiatr Res; 2002; 36(6):383-90. PubMed ID: 12393307
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study.
    Seguí J; López-Muñoz F; Alamo C; Camarasa X; García-García P; Pardo A
    J Psychopharmacol; 2010 Aug; 24(8):1201-7. PubMed ID: 19282423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.
    Mallinckrodt CH; Prakash A; Andorn AC; Watkin JG; Wohlreich MM
    J Psychiatr Res; 2006 Jun; 40(4):337-48. PubMed ID: 16271726
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Duloxetine in treatment of anxiety symptoms associated with depression.
    Dunner DL; Goldstein DJ; Mallinckrodt C; Lu Y; Detke MJ
    Depress Anxiety; 2003; 18(2):53-61. PubMed ID: 12964171
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between major depressive disorder and associated painful physical symptoms: analysis of data from two pooled placebo-controlled, randomized studies of duloxetine.
    Robinson MJ; Sheehan D; Gaynor PJ; Marangell LB; Tanaka Y; Lipsius S; Ohara F; Namiki C
    Int Clin Psychopharmacol; 2013 Nov; 28(6):330-8. PubMed ID: 23873291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine.
    Bose A; Tsai J; Li D
    Clin Drug Investig; 2012 Jun; 32(6):373-85. PubMed ID: 22559255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life.
    Kuga A; Tsuji T; Hayashi S; Fujikoshi S; Tokuoka H; Yoshikawa A; Escobar R; Tanaka K; Azekawa T
    Neuropsychiatr Dis Treat; 2017; 13():2115-2124. PubMed ID: 28831260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.
    Arnold LM; Rosen A; Pritchett YL; D'Souza DN; Goldstein DJ; Iyengar S; Wernicke JF
    Pain; 2005 Dec; 119(1-3):5-15. PubMed ID: 16298061
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials.
    Lam RW; Andersen HF; Wade AG
    Int Clin Psychopharmacol; 2008 Jul; 23(4):181-7. PubMed ID: 18545055
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial.
    Upadhyaya HP; Arnold LM; Alaka K; Qiao M; Williams D; Mehta R
    Pediatr Rheumatol Online J; 2019 May; 17(1):27. PubMed ID: 31138224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.